Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 14

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Apr 14, 2014; 20(14): 3858-3874
Published online Apr 14, 2014. doi: 10.3748/wjg.v20.i14.3858

Table 2 Summary of key biomarkers investigated in clinical trials of bevacizumab

Key biomarkers evaluated
KRAS mutational status
BRAF mutational status
p53 mutational status
VEGF and VEGFR-2 (KDR) gene expression
VEGF A- to VEGF-D, VEGFR-1, and VEGFR-2 protein expression
CD31 expression
Neuropilin expression
Stromal thrombospondin-2 expression
Microvessel density
Plasma VEGF levels

VEGF: Vascular endothelial growth factor.

Citation: Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014; 20(14): 3858-3874
URL: https://www.wjgnet.com/1007-9327/full/v20/i14/3858.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i14.3858

Luo HY, Xu RH. Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. World J Gastroenterol 2014; 20(14): 3858-3874 [PMID: 24744578 DOI: 10.3748/wjg.v20.i14.3858]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.